Compare MGIH & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIH | CLGN |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Publishing | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 18.4M |
| IPO Year | 2022 | 2015 |
| Metric | MGIH | CLGN |
|---|---|---|
| Price | $1.50 | $0.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 4.5K | ★ 146.6K |
| Earning Date | 10-28-2025 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $240.45 |
| Revenue Next Year | N/A | $38.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $0.27 |
| 52 Week High | $4.84 | $4.98 |
| Indicator | MGIH | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 44.14 |
| Support Level | $1.38 | $0.27 |
| Resistance Level | $1.53 | $0.73 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 71.79 | 69.51 |
Millennium Group International Holdings Ltd supplies paper-based packaging solutions, including inner packaging boxes produced with offset or flexo printing and outer corrugated boxes used for transportation, storage, pallets, and point-of-purchase displays. The company manufactures corrugated products of different sizes, shapes, thicknesses, and strengths according to customer specifications. It also operates a supply chain management business in Vietnam to service international clients who source their packaging needs from Vietnam and other ASEAN countries. The corrugated paper is durable, versatile, economical, and lightweight.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.